In a non‑anuric, euvolemic acute kidney injury patient without a known loop‑diuretic allergy, what is the recommended management for Furosemide Stress Test (FST) responders (patients producing >200 mL urine within 2 hours after a standardized furosemide bolus)?

Management of FST Responders in Non-Anuric, Euvolemic AKI

In FST responders (>200 mL urine output within 2 hours), continue conservative management with close monitoring rather than initiating renal replacement therapy, as these patients demonstrate preserved tubular function and have significantly lower risk of requiring dialysis.

Rationale for Conservative Management

FST responders represent a fundamentally different risk category than non-responders. The evidence consistently demonstrates that patients producing >200 mL urine within 2 hours after furosemide administration have:

• Dramatically lower RRT rates: Only 8-37.5% of FST responders require RRT compared to 72.7-89.2% of non-responders 1, 2
• Preserved tubular reserve: The ability to respond to furosemide indicates functional nephron mass capable of recovery 1
• Better short-term kidney recovery: FST-positive patients show successful liberation from RRT in 85.5% of cases 1

The 2025 American Journal of Kidney Diseases guidelines emphasize that spot urine sodium measurement 2 hours after diuretic administration reliably predicts subsequent natriuresis, with urine output <100-150 mL/hour during the first 6 hours denoting insufficient response 3. Your FST responder exceeds this threshold, indicating adequate diuretic response.

Specific Management Algorithm

Immediate Actions (First 24 Hours)

1. Monitor urine output hourly: Target maintenance of >100-150 mL/hour for the first 6 hours
2. Check spot urine sodium at 2 hours: Should be ≥50-70 mEq/L indicating adequate natriuresis 3
3. Measure serum electrolytes: Potassium, sodium, creatinine, BUN every 12-24 hours initially 4
4. Assess volume status: Daily weights, clinical examination for fluid overload

Diuretic Management

Do not escalate diuretic therapy in FST responders unless volume overload develops. The KDIGO guidelines explicitly recommend against using diuretics to treat AKI except for volume overload management 5. Since your patient is euvolemic, additional diuretics risk:

• Volume depletion and hypotension 4
• Electrolyte depletion (hypokalemia, hyponatremia, hypochloremic alkalosis) 4
• Worsening renal perfusion 4

Monitoring Parameters

Electrolyte surveillance (per FDA labeling 4):

• Serum potassium, sodium, chloride, CO2, creatinine, BUN
• Watch for hypokalemia (especially with brisk diuresis), hyponatremia, hypochloremic alkalosis
• Magnesium and calcium levels periodically

Clinical signs of fluid/electrolyte imbalance 4:

• Dryness of mouth, thirst, weakness, lethargy
• Muscle cramps, muscular fatigue
• Hypotension, oliguria, tachycardia, arrhythmia
• Gastrointestinal disturbances

Medication Review

Avoid nephrotoxic agents 6:

• NSAIDs (reduce renal perfusion and compete for tubular secretion)
• Aminoglycosides (increased ototoxicity risk with furosemide) 4
• ACE inhibitors/ARBs if hypotension develops (risk severe hypotension and renal deterioration) 4

Adjust existing medications:

• Lithium: Generally contraindicated with diuretics (reduced clearance, toxicity risk) 4
• Digoxin: Monitor levels if used (hypokalemia potentiates toxicity) 4

Common Pitfalls to Avoid

1. Over-diuresis: FST responders don't need aggressive diuresis. Excessive diuretic use causes volume depletion, hypotension, and paradoxical worsening of renal function 4

2. Premature RRT initiation: The 2025 data shows FST responders have 85.5% successful RRT liberation rates 1. Avoid dialysis unless absolute indications develop (severe hyperkalemia, pulmonary edema, uremic complications)

3. Ignoring electrolyte abnormalities: Hypokalemia develops rapidly with loop diuretics, especially with inadequate oral intake 4. Correct abnormalities promptly rather than withdrawing necessary therapy

4. Inadequate monitoring: The first weeks require frequent clinical and biochemical assessment 7. FST responders still have AKI and need close observation

Prognostic Implications

The FST response provides critical prognostic information. Studies demonstrate:

• AUC 0.87-0.966 for predicting successful RRT discontinuation or avoidance 1, 2
• Sensitivity 94.85%, specificity 98.04% at 156 mL cutoff for CRRT initiation 2
• Earlier risk stratification: FST enables prediction at median 5 hours versus 18 hours with KDIGO criteria 8

Your FST responder has demonstrated tubular reserve, suggesting preserved nephron function and high likelihood of renal recovery without RRT 1.

When to Escalate Care

Initiate RRT only if absolute indications develop:

• Severe hyperkalemia (>6.5 mEq/L) refractory to medical management
• Pulmonary edema unresponsive to diuretics
• Severe metabolic acidosis (pH <7.1)
• Uremic complications (pericarditis, encephalopathy, bleeding)
• Severe azotemia with symptoms

The FACTT-lite protocol for ARDS patients (applicable to AKI without shock) provides a framework: with adequate urine output (≥0.5 mL/kg/h) and CVP >8, give furosemide and reassess in 4 hours 9. However, in your euvolemic FST responder, no intervention with reassessment in 4 hours is most appropriate.

3, 9, 3, 9, 5, 4, 1, 2, 8